After second dose, Pfizer’s efficacy declined from 96% down to 84%
The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and
Read moreThe Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and
Read moreYesterday, brought the good news that Pfizer and its partner BioNTech would start manufacturing its COVID-19 vaccines in Africa, for Africa. By ERIKA
Read morePfizer and BioNTech said they would seek authorization for a third dose of their Covid-19 vaccine to boost its efficacy
Read morePfizer is planning to seek U.S. authorization for a third dose of its COVID-19 vaccine, saying Thursday that another shot
Read morePfizer plans to tap the mRNA technology to make new vaccines for other viruses following the success of its Covid-19
Read moreLate stage vaccine trials, The first large study of the safety and effectiveness of a coronavirus vaccine in the United
Read more